(PHIA) Koninklijke Philips - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0000009538
Stock: Diagnostics, Imaging, Ultrasound, Patient, Health, Devices
Total Rating 45
Risk 82
Buy Signal -0.63
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.87% |
| Yield on Cost 5y | 2.35% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 81.6% |
| Payout Ratio | 98.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.9% |
| Relative Tail Risk | -21.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -11.43 |
| Character TTM | |
|---|---|
| Beta | 0.269 |
| Beta Downside | 0.538 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.92% |
| CAGR/Max DD | 0.78 |
Description: PHIA Koninklijke Philips December 17, 2025
Koninklijke Philips N.V. (PHIA) is a global health-technology firm that serves North America, Greater China and the rest of the world through three core segments: Diagnosis & Treatment, Connected Care and Personal Health. Its portfolio spans diagnostic imaging (MRI, X-ray, CT, ultrasound), interventional X-ray systems and software, acute and emergency patient-management solutions, as well as consumer-focused products such as power toothbrushes, infant-care devices and personal-wellness gadgets.
In FY 2023 Philips generated €22.5 billion in revenue, with the Connected Care segment posting a 12 % year-over-year growth rate-driven by rising demand for remote monitoring and AI-enabled care coordination. R&D intensity remains high at roughly 7 % of sales, reflecting the company’s focus on digital health integration, while operating margins have been pressured to 5.8 % due to supply-chain constraints. Key macro-drivers include an aging global population, increasing healthcare-spending ratios in emerging markets, and accelerated adoption of vendor-agnostic software platforms that enable hospitals to modernize legacy equipment.
For a data-rich, quantitative deep-dive on PHIA’s valuation dynamics, check the ValueRay research page.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 165.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -3.02 > 1.0 |
| NWC/Revenue: 12.64% < 20% (prev 9.16%; Δ 3.48% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.16b > Net Income 165.0m |
| Net Debt (6.47b) to EBITDA (1.95b): 3.32 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (963.8m) vs 12m ago 3.43% < -2% |
| Gross Margin: 43.49% > 18% (prev 0.42%; Δ 4307 % > 0.5%) |
| Asset Turnover: 63.79% > 50% (prev 61.34%; Δ 2.45% > 0%) |
| Interest Coverage Ratio: 3.49 > 6 (EBITDA TTM 1.95b / Interest Expense TTM 270.0m) |
Altman Z'' 2.10
| A: 0.09 (Total Current Assets 9.28b - Total Current Liabilities 7.03b) / Total Assets 26.34b |
| B: 0.12 (Retained Earnings 3.21b / Total Assets 26.34b) |
| C: 0.03 (EBIT TTM 943.2m / Avg Total Assets 27.87b) |
| D: 0.87 (Book Value of Equity 13.76b / Total Liabilities 15.76b) |
| Altman-Z'' Score: 2.10 = BBB |
Beneish M -3.30
| DSRI: 0.78 (Receivables 3.27b/4.26b, Revenue 17.78b/18.04b) |
| GMI: 0.97 (GM 43.49% / 42.18%) |
| AQI: 0.98 (AQ_t 0.56 / AQ_t-1 0.58) |
| SGI: 0.99 (Revenue 17.78b / 18.04b) |
| TATA: -0.04 (NI 165.0m - CFO 1.16b) / TA 26.34b) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of PHIA shares?
As of February 07, 2026, the stock is trading at EUR 24.79 with a total of 1,348,794 shares traded.
Over the past week, the price has changed by +2.74%, over one month by +1.39%, over three months by +1.43% and over the past year by -3.00%.
Over the past week, the price has changed by +2.74%, over one month by +1.39%, over three months by +1.43% and over the past year by -3.00%.
Is PHIA a buy, sell or hold?
Koninklijke Philips has no consensus analysts rating.
What are the forecasts/targets for the PHIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.8 | 8.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.8 | 0.1% |
PHIA Fundamental Data Overview February 03, 2026
Market Cap USD = 27.35b (23.18b EUR * 1.1801 EUR.USD)
P/E Trailing = 152.3125
P/E Forward = 15.7978
P/S = 1.3035
P/B = 2.1846
P/EG = 0.3634
Revenue TTM = 17.78b EUR
EBIT TTM = 943.2m EUR
EBITDA TTM = 1.95b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.38b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 29.65b EUR (23.18b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 3.49 (Ebit TTM 943.2m / Interest Expense TTM 270.0m)
EV/FCF = 112.3x (Enterprise Value 29.65b / FCF TTM 264.0m)
FCF Yield = 0.89% (FCF TTM 264.0m / Enterprise Value 29.65b)
FCF Margin = 1.48% (FCF TTM 264.0m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.13 (Enterprise Value 29.65b / Total Assets 26.34b)
Interest Expense / Debt = 0.68% (Interest Expense 57.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 644.8m (EBIT 943.2m * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 3.32 (Net Debt 6.47b / EBITDA 1.95b)
Debt / FCF = 24.52 (Net Debt 6.47b / FCF TTM 264.0m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 5.13% (EBIT 943.2m / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 3.42% (NOPAT 644.8m / Invested Capital 18.86b)
WACC = 5.20% (E(23.18b)/V(31.56b) * Re(6.91%) + D(8.38b)/V(31.56b) * Rd(0.68%) * (1-Tc(0.32)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.95%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈631.2m ; Y1≈414.3m ; Y5≈189.1m
Fair Price DCF = N/A (negative equity: EV 6.02b - Net Debt 6.47b = -449.2m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 8.34 | EPS CAGR: -9.80% | SUE: 0.13 | # QB: 0
Revenue Correlation: -6.22 | Revenue CAGR: -3.64% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.30 | Chg30d=-0.007 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.52 | Chg30d=-0.017 | Revisions Net=-7 | Growth EPS=+10.1% | Growth Revenue=+1.1%
P/E Trailing = 152.3125
P/E Forward = 15.7978
P/S = 1.3035
P/B = 2.1846
P/EG = 0.3634
Revenue TTM = 17.78b EUR
EBIT TTM = 943.2m EUR
EBITDA TTM = 1.95b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.38b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 29.65b EUR (23.18b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 3.49 (Ebit TTM 943.2m / Interest Expense TTM 270.0m)
EV/FCF = 112.3x (Enterprise Value 29.65b / FCF TTM 264.0m)
FCF Yield = 0.89% (FCF TTM 264.0m / Enterprise Value 29.65b)
FCF Margin = 1.48% (FCF TTM 264.0m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.13 (Enterprise Value 29.65b / Total Assets 26.34b)
Interest Expense / Debt = 0.68% (Interest Expense 57.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 644.8m (EBIT 943.2m * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 3.32 (Net Debt 6.47b / EBITDA 1.95b)
Debt / FCF = 24.52 (Net Debt 6.47b / FCF TTM 264.0m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 5.13% (EBIT 943.2m / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 3.42% (NOPAT 644.8m / Invested Capital 18.86b)
WACC = 5.20% (E(23.18b)/V(31.56b) * Re(6.91%) + D(8.38b)/V(31.56b) * Rd(0.68%) * (1-Tc(0.32)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.95%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈631.2m ; Y1≈414.3m ; Y5≈189.1m
Fair Price DCF = N/A (negative equity: EV 6.02b - Net Debt 6.47b = -449.2m; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 8.34 | EPS CAGR: -9.80% | SUE: 0.13 | # QB: 0
Revenue Correlation: -6.22 | Revenue CAGR: -3.64% | SUE: -0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.30 | Chg30d=-0.007 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.52 | Chg30d=-0.017 | Revisions Net=-7 | Growth EPS=+10.1% | Growth Revenue=+1.1%